CagriSema side effects and risks

Reported side effects

• Stomach and bowel symptoms: 79.6% versus 39.9% placebo in REDEFINE 1; 72.5% versus 34.4% in REDEFINE 2., moderate (source)
• Nausea: REIMAGINE 3: 31.1% at 2.4 mg each, 26.9% at 1 mg each, 3.3% placebo., moderate (source)
• Diarrhea: REIMAGINE 3: 15.6%, 10.8% and 3.3%, respectively., moderate (source)
• Vomiting: REIMAGINE 3: 14.4%, 9.7% and 1.1%, respectively., moderate (source)
• Constipation: REIMAGINE 3: 11.1%, 11.8% and 5.5%, respectively., moderate (source)
• Injection-site reactions: 12.2% versus 3.0% placebo in REDEFINE 1., mild (source)
• Gallbladder disorders: 4.1% versus 1.0% placebo in REDEFINE 1., serious (source)
• Pancreatitis: 0.2% versus 0% placebo in REDEFINE 1; 0.3% versus 0% in REDEFINE 2., serious (source)
• Clinically significant low blood sugar: REDEFINE 2: level 2 events 6.0% versus 3.3% placebo., serious (source)
• Severe low blood sugar: REDEFINE 2: 0.2% versus 0%; both affected patients used sulfonylureas., serious (source)
• Dehydration-related kidney injury: Semaglutide component warning; no reliable combination specific rate., serious (source)
• Severe allergic reaction: Semaglutide component postmarketing reports; combination specific rate unknown., serious (source)

Stop and get help if

• Severe persistent belly pain, with or without vomiting: Stop and get urgent assessment for pancreatitis or gallbladder disease.
• Swelling of face or throat, breathing trouble or collapse: Stop and call emergency services.
• Confusion, seizure, unconsciousness or persistent low sugar: Call emergency services; do not give food or drink if unconscious.
• Repeated vomiting, very little urine or severe dizziness: Get urgent assessment for dehydration and kidney injury.
• Sudden vision loss or a new major vision change: Get emergency care for sudden loss of sight; urgent assessment for other new changes.
• Persistent squeezing chest pain, or chest pain with breathlessness: Get emergency assessment.

Who should avoid it

• pregnant: Weight-loss use is unsuitable in pregnancy; semaglutide may harm the fetus.
• breastfeeding: The combination lacks infant safety data; breastfeeding was excluded from trials.
• tryingToConceive: Semaglutide labeling calls for stopping at least 2 months before planned pregnancy.
• under18: Combination dosing in youth is still under study; adult results do not establish safety.
• mtcOrMen2: Semaglutide's label blocks use with personal/family MTC or MEN2. Its boxed warning reports thyroid C-cell tumors in rodents; human relevance is unknown, and CagriSema has no approved label.
• eatingDisorderHistory: Precaution: strong appetite suppression can worsen restrictive eating or poor nutrition.
• gastroparesis: Semaglutide is not recommended with severe gastroparesis.
• pancreatitisHistory: Review prior pancreatitis; cases occurred in combination trials.
• gallbladderDisease: Gallbladder events were more frequent than placebo in REDEFINE trials.
• diabeticRetinopathy: Rapid glucose improvement may worsen existing retinopathy; arrange eye monitoring.
• diabetes: Insulin or sulfonylureas may need clinician adjustment to avoid low blood sugar.
• kidneyDisease: Vomiting or diarrhea can cause dehydration and kidney injury; check kidney function if symptoms persist.
• liverDisease: Component PK data do not establish long-term combination safety in severe liver disease.
• heartCondition: Monitor heart rate and symptoms; combination cardiovascular outcomes are still pending.
• surgeryPlanned: Tell the anesthesia team; delayed stomach emptying can increase aspiration risk.
• testedAthlete: Cagrilintide remains unapproved, so S0 applies; semaglutide monitoring is a separate issue.
• other: Prior serious allergy to semaglutide, cagrilintide or formulation ingredients should stop use.

Interactions

• Insulin and sulfonylureas: Low-sugar risk can rise. Both severe cases in REDEFINE 2 used sulfonylureas; clinician-led dose review matters.
• Extra GLP-1 or amylin drugs: CagriSema already contains semaglutide and cagrilintide. Added GLP-1 or amylin exposure has no established safe schedule.
• Warfarin and other monitored oral drugs: Review INR or drug response during changes. The dedicated warfarin/atorvastatin study is complete but results were not located.
• Oral contraception: Combination absorption data are incomplete. Vomiting or diarrhea can undermine pill use; review backup needs with a clinician.

Product quality risks

• A community “CagriSema” blend is not the controlled dual-chamber trial product.
• Online semaglutide samples had 7.7–14.37% purity, 28.56–38.69% excess content and detectable endotoxin. This was not a CagriSema test.
• Wrong component ratio, vial/unit confusion and contamination can cause harm.
• FDA warns of counterfeit semaglutide products and dosing errors with unapproved injections.